Plain-English translation of NCT06611436 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia B research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for adults with moderate to severe hemophilia B, a genetic bleeding disorder. is a cell-based therapy designed to help your body produce more of the clotting factor that's missing in hemophilia B. The study will test different doses of this medication to find the safest and most effective level.
Current hemophilia B treatments require regular infusions to replace the missing clotting factor, which can be burdensome for patients. This trial is exploring whether a one-time cellular treatment could provide longer-lasting clotting factor production, potentially reducing the need for frequent infusions.
You would first undergo a screening visit to confirm you qualify. If enrolled, you'll have a procedure called leukapheresis where blood cells are collected from you and used to create the medication. You'll then receive an infusion of the treatment and return for regular check-ups over approximately one year to monitor how well it works and check for any side effects.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States